• Users Online: 1152
  • Print this page
  • Email this page
Year : 2023  |  Volume : 3  |  Issue : 2  |  Page : 433-435

Response of a single-dose intravitreal brolucizumab in type 3 macular neovascularization

1 Department of Vitreoretinal Services, Retina Institute of Bengal, Pradhan Nagar, Siliguri, West Bengal, India
2 Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, India

Correspondence Address:
Somnath Chakraborty
Retina Institute of Bengal, Pradhan Nagar, Siliguri - 734 003, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IJO.IJO_2957_22

Rights and Permissions

The authors describe a case of an 82-year-old female with type 3 macular neovascularization (MNV) who underwent a single-dose of intravitreal injection (IVI) of brolucizumab at baseline. The patient demonstrated significant visual improvement from 20/400 at baseline to 20/32 at 3 months without any significant adverse events. Notably, there was complete resolution of the subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hyperreflective material (SHRM) at 1 month postinjection, which was maintained for up to 3 months. Further prospective studies with a larger sample size are warranted to better understand the morphological and visual responses of type 3 MNV to brolucizumab therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal